Endocrine Abstracts

Background: The extent of biochemical abnormalities in household members of children presenting with symptomatic vitamin D deficiency remains unknown. Characterising risk groups who warrant 25 hydroxyvitamin D (25OHD) testing will help reduce the rising frequency of unnecessary testing in the UK.Aims: Investigate the prevalence of vitamin D deficiency and biochemical osteomalacia in the mothers and siblings of children presenting with symptomatic vitamin...

Objectives: Examine the effect of maternal Index of Multiple Deprivation (IMD) on newborn 25-hydroxyvitaminD (25OHD) levels in a multi-ethnic newborn cohort.Design: 3000 dried blood spots (DBS) were gathered from newborns at a regional newborn screening laboratory over two 1-week periods [February 2019 (winter) and August 2019 (summer)]. Data on birth weight, gestational age, maternal age, ethnicity, and post code were collected. Post code was replaced w...

Introduction: NICE recommends annual screening for diabetic retinopathy in children with type 1 diabetes aged over 12 years and/or with duration of diabetes over 5 years. This audit aimed to evaluate patient attendance for retinopathy screening, to identify the prevalence of retinopathy and maculopathy and to ascertain characteristics of patients.Methods: This was a retrospective audit of patients attending for eye screening from January 2008 to April 20...

Introduction: Giant cell tumour of bone (GCTB) is a benign, locally aggressive tumour whose neoplastic stromal cells express receptor activator of nuclear factor kappa-B ligand (RANKL) and activate its receptor RANK on osteoclast-like giant cells. Denosumab (RANKL inhibitor) is an FDA/EMA approved treatment for GCTB in adults and ‘skeletally mature’ adolescents. Safety concerns include oversuppression of bone remodelling, with risk of osteonecrosis of the jaw (ONJ) a...